Evaluation of the oral delivery of a peptide with Pheroid® technology
Date
2019Author
Erasmus, Linné
Scholtz, Liezl-Marie
Venter, Kobus
Bester, Cor
Fick, Antoinette
Mabena, Jacob
Grobler, Anne
Hayeshi, Rose
Metadata
Show full item recordAbstract
Goserelin is a type of hormone therapy used in addition to standard
adjuvant therapy. Currently, goserelin is only available as a slow
releasing subcutaneous implant but this is an invasive and generally not well- tolerated method of administration. By using a drug delivery
system (DDS), peptides can be protected from the harsh environment
of the gastrointestinal (GI) tract. Pheroid® technology is one such
example of a drug delivery system. This delivery system is a patented,
colloidal drug delivery system and is capable of targeting specific areas
for treatment, transportation of genetic material to the cellular nucleus
and the decrease of drug resistance, all this while improving the
delivery of dynamic complexes [1,2]. The prospect of changing to a less
invasive administration method will yield a great advantage. Goserelin
was investigated in female Balb/c mice. Pheroid® technology was used
as a drug delivery system (DDS) to compare the bioavailability of
goserelin subcutaneous depot against a peroral formulation with
goserelin pro-Pheroid® formulation. The mice were divided into three
groups; group one received goserelin subcutaneously, group 2
received an oral dose of 4 mg/kg pro-Pheroid®-goserelin and group
3 being the control group which received only pro- Pheroid®. Vaginal
cytology was evaluated to track the disruption of the oestrus cycle
Vaginal cytology results indicated a disruption in the oestrus cycle in
the subcutaneous groups and the pro- Pheroid®-goserelin oral group.
No disruption in the cycle was observed for the pro-Pheroid® oral
group. Entrapment in Pheroid® resulted in oral bioavailability of
goserelin as indicated by the related effect on the oestrus cycle. No
disruption of the cycle was observed in the pro-pheroid® oral group,
thus, goserelin was successfully absorbed in the blood after the peroral
administration with pro-Pheroid. In conclusion, Pheroid® technology
seemed to protect goserelin from the harsh environment of the
gastrointestinal tract and could thus be a helpful DDS
URI
http://hdl.handle.net/10394/33312https://www.sciencedirect.com/science/article/pii/S1056871919303260
https://doi.org/10.1016/j.vascn.2019.106608